Compare · NVO vs SDEV
NVO vs SDEV
Side-by-side comparison of Novo Nordisk A/S (NVO) and Stablecoin Development Corporation (SDEV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SDEV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 3289.9x SDEV ($52.8M).
- Over the past year, NVO is down 28.6% and SDEV is down 83.1% - NVO leads by 54.5 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for SDEV).
- Company
- Novo Nordisk A/S
- Stablecoin Development Corporation
- Price
- -
- -
- Market cap
- $173.66B
- $52.8M
- 1M return
- -10.14%
- +7.61%
- 1Y return
- -28.57%
- -83.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest SDEV
- Amendment: SEC Form S-3/A filed by Stablecoin Development Corporation
- Stablecoin Development Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Stablecoin Development Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Stablecoin Development Corporation
- Amendment: SEC Form S-3/A filed by Stablecoin Development Corporation
- SEC Form 3 filed by new insider Rios David Garcia
- Stablecoin Development Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
- SEC Form S-3 filed by Stablecoin Development Corporation
- Stablecoin Development Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results